A Multicenter, Randomized, Phase III Trial of Chemotherapy Followed by 6-month or 12-month Icotinib Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation

Trial Profile

A Multicenter, Randomized, Phase III Trial of Chemotherapy Followed by 6-month or 12-month Icotinib Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2016

At a glance

  • Drugs Icotinib (Primary) ; Antineoplastics
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ICTAN
  • Most Recent Events

    • 13 Apr 2016 Planned End Date changed from 1 Jan 2021 to 1 Jan 2023 as reported by ClinicalTrials.gov record.
    • 13 Apr 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2018 as reported by ClinicalTrials.gov record.
    • 01 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top